The DOI matches its Crossref record.
Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues.
Open accessAbstract
Genetic and biochemical evidence suggests that the Ras protooncogene product regulates the activation of the Raf kinase pathway, leading to the proposal that Raf is a direct mitogenic effector of activated Ras. Here we report the use of a novel competition assay to measure in vitro the relative affinity of the c-Raf-1 regulatory region for Ras-GTP, Ras-GDP, and 10 oncogenic and effector mutant Ras proteins. c-Raf-1 associates with normal Ras and the oncogenic V12 and L61 forms of Ras with equal affinity. The moderately transforming mutant Ras[E30K31] also bound to the c-Raf-1 regulatory region with normal affinity. Transformation-defective Ras effector mutants Ras[N33], Ras[S35], and Ras[N38] bound poorly. In contrast, the transformation defective Ras[G26I27] and Ras[E45] mutants bound to the c-Raf-1 regulatory region with nearly wild-type affinity. A stable, high-affinity Ras-binding region of c-Raf-1 was mapped to a 99-amino-acid subfragment of the first 257 residues. The smallest Ras-binding region identified consisted of N-terminal residues 51 to 131, although stable expression of the domain and high-affinity binding were improved by the presence of residues 132 to 149. Deletion of the Raf zinc finger region did not reduce Ras-binding affinity, while removal of the first 50 amino acids greatly increased affinity. Phosphorylation of Raf[1-149] by protein kinase A on serine 43 resulted in significant inhibiton of Ras binding. demonstrating that the mechanism of cyclic AMP downregulation results through structural changes occurring exclusively in this small Ras-binding domain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rheb Binds and Regulates the mTOR Kinase
Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., & Avruch, J. (2005) · Current Biology · doi:10.1016/j.cub.2005.02.053 · Cited by 1,005
Self-citationRegulation of RAF protein kinases in ERK signalling
Lavoie, H., & Therrien, M. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3979 · Cited by 702
Nassar, N., Horn, G., Herrmann, C. A., Scherer, A., McCormick, F., & Wittinghofer, A. (1995) · Nature · doi:10.1038/375554a0 · Cited by 635
A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK
Enserink, J. M., Christensen, A. E., de Rooij, J., van Triest, M., Schwede, F., Genieser, H. G., Døskeland, S. O., Blank, J. L., & Bos, J. L. (2002) · Nature Cell Biology · doi:10.1038/ncb874 · Cited by 625
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M., & Watson, I. R. (2018) · Oncogene · doi:10.1038/s41388-018-0171-x · Cited by 550
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Degirmenci, U., Wang, M., & Hu, J. (2020) · Cells · doi:10.3390/cells9010198 · Cited by 534
Raf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
Regulation and Role of Raf-1/B-Raf Heterodimerization
Rushworth, L. K., Hindley, A. D., O'Neill, E., & Kolch, W. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2262-2272.2006 · Cited by 418
Cell cycle-dependent activation of Ras
Taylor, S. J., & Shalloway, D. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70785-9 · Cited by 388
Physiological Substrates of cAMP-Dependent Protein Kinase
Shabb, J. B. (2001) · Chemical Reviews · doi:10.1021/cr000236l · Cited by 373
Insulin signal transduction through protein kinase cascades
Avruch, J. (1998) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006823109415 · Cited by 365
Self-citationRas Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
Herrmann, C., Martin, G. A., & Wittinghofer, A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.7.2901 · Cited by 350
Nonaka, H., Tanaka, K., Hirano, H., Fujiwara, T., Kohno, H., Umikawa, M., Mino, A., & Takai, Y. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00281.x · Cited by 341
Herrmann, C., Horn, G., Spaargaren, M., & Wittinghofer, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.12.6794 · Cited by 328
Raf kinases: Function, regulation and role in human cancer
Leicht, D. T., Balan, V., Kaplun, A., Singh-Gupta, V., Kaplun, L., Dobson, M., & Tzivion, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.05.001 · Cited by 317
Cantor, S. B., Urano, T., & Feig, L. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4578 · Cited by 310
Ras target proteins in eukaryotic cells
Marshall, M. S. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.13.7557021 · Cited by 309
Self-citationRaf: A Strategic Target for Therapeutic Development Against Cancer
Beeram, M., Patnaik, A., & Rowinsky, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.036 · Cited by 298
Malarkey, K., Belham, C. M., Paul, A., Graham, A., McLees, A., Scott, P. H., & Plevin, R. (1995) · Biochemical Journal · doi:10.1042/bj3090361 · Cited by 268
Deconstruction of the Ras switching cycle through saturation mutagenesis
Bandaru, P., Shah, N. H., Bhattacharyya, M., Barton, J. P., Kondo, Y., Cofsky, J. C., Gee, C. L., Chakraborty, A. K., Kortemme, T., Ranganathan, R., et al. (2017) · eLife · doi:10.7554/elife.27810 · Cited by 117
“Many mutations in Switch I, such as D33N, T35S, and D38N, lead to a greater than 100-fold increase in the value of KD relative to wild-type, corresponding to values of DDGbinding that range from 3 to 10 kJ/mol.”
BackgroundInfluentialSeah, C., Phillips, T. J., Howard, C. E., Panova, I. P., Hayes, C. M., Asandra, A. S., & Park, H.-Y. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23557.x · Cited by 74
Akasaka, K., Tamada, M., Wang, F., Kariya, K.-I., Shima, F., Kikuchi, A., Yamamoto, M., Shirouzu, M., Yokoyama, S., & Kataoka, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5353 · Cited by 69
A systems mechanism for KRAS mutant allele–specific responses to targeted therapy
McFall, T., Diedrich, J. K., Mengistu, M., Littlechild, S. L., Paskvan, K. V., Sisk-Hackworth, L., Moresco, J. J., Shaw, A. S., & Stites, E. C. (2019) · Science Signaling · doi:10.1126/scisignal.aaw8288 · Cited by 65
Microtubule Integrity Regulates Pak Leading to Ras-independent Activation of Raf-1
Zang, M., Waelde, C. A., Xiang, X., Rana, A., Wen, R., & Luo, Z. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100152200 · Cited by 48
Metadata
- Authors
- Chuang, E., Barnard, D., Hettich, L., Zhang, X. F., Avruch, J., & Marshall, M. S.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1994-08
- Volume
- 14
- Issue
- 8
- Pages
- 5318-5325
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W1897773958
- Cited by
- 184
- References
- 0
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.